
Sign up to save your podcasts
Or


The first half of 2025 was decidedly mixed for many publicly traded healthcare companies, and they’re facing murky waters in the back half of the year amid policy and cost upheaval.
In this episode of "Podnosis," Fierce Healthcare Associate Editor Dave Muoio and Senior Writer Paige Minemyer break down the topline takeaways from another round of corporate earnings calls, including a look at executive commentary on the “big, beautiful” policy environment.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
By Fierce Healthcare4.7
33 ratings
The first half of 2025 was decidedly mixed for many publicly traded healthcare companies, and they’re facing murky waters in the back half of the year amid policy and cost upheaval.
In this episode of "Podnosis," Fierce Healthcare Associate Editor Dave Muoio and Senior Writer Paige Minemyer break down the topline takeaways from another round of corporate earnings calls, including a look at executive commentary on the “big, beautiful” policy environment.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.

4,654 Listeners

4,338 Listeners

1,090 Listeners

30,192 Listeners

2,348 Listeners

334 Listeners

56,509 Listeners

225 Listeners

494 Listeners

9,523 Listeners

322 Listeners

195 Listeners

391 Listeners

611 Listeners

165 Listeners